ReviewOpen Access
Enterotoxigenic Escherichia coli (ETEC) vaccines: Priority activities to enable product development, licensure, and global access
Authors
Author Affiliations
Patuakhali Science and Technology University, Program for Appropriate Technology in Health, Centre for Infectious Disease Research in Zambia, Universidad Nacional Autónoma de México, ...
Published InVaccine
Year2021
Citations116
Abstract
Diarrhoeal disease attributable to enterotoxigenic Escherichia coli (ETEC) causes substantial morbidity and mortality predominantly in paediatric populations in low- and middle-income countries. In addition to acute illness, there is an increasing appreciation of the long-term consequences of enteric infections, including ETEC, on childhood growth and development. Provision of potable water and sanitation and appropriate clinical care for acute illness are critical to reduce the ETEC burden. However, these interventions are not always practical and may not achieve equitable and sustainable coverage. Vaccination may be the most cost-effective and equitable means of primary prevention; however, additional data are needed to accelerate the investment and guide the decision-making process for ETEC vaccines. First, to understand and quantify the ETEC disease burden, additional…
View at Publisher
BORR does not host full-text PDFs. The button above takes you to the original publisher.